Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 22, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 22, 2024 -- An estimated 100,429 youth are living with pediatric inflammatory bowel disease (PIBD) in the United States, according to a research letter published online Nov. 20 in Gastroenterology.

Michael D. Kappelman, M.D., M.P.H., from the University of North Carolina at Chapel Hill, and colleagues analyzed two commercial insurance claims datasets along with data from five state Medicaid plans to describe the prevalence of PIBD among individuals younger than 20 years.

The researchers found that the age-, sex-, and insurance status-standardized prevalence per 100,000 population was 122 for IBD, 71 for Crohn disease (CD), and 44 for ulcerative colitis (UC). Based on a 2020 U.S. census population, an estimated 100,429 American youth are living with IBD, including 58,733 with CD and 36,270 with UC. All prevalence rates increased with age. The prevalence of CD was higher in males than females. There was variation observed in prevalence by race and ethnicity, with prevalence rates of 145, 91, 52, and 88 per 100,00 population in White, Black, Asian, and Hispanic Americans, respectively. Over time, there was a slight increase seen in PIBD, from 110 per 100,000 in 2011 to 119, 126, and 125 per 100,000 in 2014, 2017, and 2020, respectively.

"These data can be used to inform health policy and resource allocation and suggest the need for future investigation to better understand the causes and consequences of observed differences based on geography, race, and ethnicity," the authors write.

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords